The decreased sensitivity to MEK inhibition in cancer cells containing oncogenic KRAS mutations is likely due to another RAS-effector pathways (e.g. PI3K pathway) that can maintain cell proliferation and survival (Figure 4B). This evidence concerns the gene MAP2K7 and cancer.